[go: up one dir, main page]

CO7131353A2 - Tratamiento de trastornos del ritmo circadiano - Google Patents

Tratamiento de trastornos del ritmo circadiano

Info

Publication number
CO7131353A2
CO7131353A2 CO14186159A CO14186159A CO7131353A2 CO 7131353 A2 CO7131353 A2 CO 7131353A2 CO 14186159 A CO14186159 A CO 14186159A CO 14186159 A CO14186159 A CO 14186159A CO 7131353 A2 CO7131353 A2 CO 7131353A2
Authority
CO
Colombia
Prior art keywords
treatment
circadian rhythm
rhythm disorders
patients
circadian
Prior art date
Application number
CO14186159A
Other languages
English (en)
Inventor
Marlene Michelle Dressman
John Joseph Feeney
Louis William Licamele
Mihael H Polymeropoulos
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47679075&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO7131353(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Publication of CO7131353A2 publication Critical patent/CO7131353A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers
    • G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2864—Sleep disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)

Abstract

Las modalidades de la invenci&oacute;n se refieren al uso de un agonista de melatonina en el tratamiento de ritmos circadianos de curso libre en los pacientes, incluidos pacientes con deficiencia de percepci&oacute;n de la luz, por ejemplo, pacientes ciegos, y a m&eacute;todos para medir el ritmo circadiano.
CO14186159A 2012-01-26 2014-08-25 Tratamiento de trastornos del ritmo circadiano CO7131353A2 (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201261590974P 2012-01-26 2012-01-26
US201261640067P 2012-04-30 2012-04-30
US201261650455P 2012-05-22 2012-05-22
US201261650458P 2012-05-22 2012-05-22
US201261714149P 2012-10-15 2012-10-15
US201261738985P 2012-12-18 2012-12-18
US201261738987P 2012-12-18 2012-12-18
US201361755896P 2013-01-23 2013-01-23

Publications (1)

Publication Number Publication Date
CO7131353A2 true CO7131353A2 (es) 2014-12-01

Family

ID=47679075

Family Applications (2)

Application Number Title Priority Date Filing Date
CO14186158A CO7131366A2 (es) 2012-01-26 2014-08-25 Tratamiento de trastornos del ritmo circadiano
CO14186159A CO7131353A2 (es) 2012-01-26 2014-08-25 Tratamiento de trastornos del ritmo circadiano

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CO14186158A CO7131366A2 (es) 2012-01-26 2014-08-25 Tratamiento de trastornos del ritmo circadiano

Country Status (21)

Country Link
US (21) US9549913B2 (es)
EP (5) EP2806863B1 (es)
JP (10) JP2015508157A (es)
KR (10) KR20140117537A (es)
CN (4) CN111603460A (es)
AU (9) AU2013211880A1 (es)
BR (2) BR112014018433A8 (es)
CA (4) CA3085116C (es)
CL (2) CL2014001992A1 (es)
CO (2) CO7131366A2 (es)
DK (1) DK2806863T3 (es)
ES (2) ES2897671T3 (es)
HR (1) HRP20171600T1 (es)
HU (1) HUE034876T2 (es)
IL (4) IL233714A0 (es)
IN (2) IN2014DN07050A (es)
MX (4) MX374068B (es)
PT (1) PT2806863T (es)
RU (2) RU2650647C2 (es)
SI (1) SI2806863T1 (es)
WO (2) WO2013112949A2 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007253701A1 (en) * 2006-05-22 2007-11-29 Vanda Pharmaceuticals, Inc. Melatonin agonist treatment
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
WO2012103411A2 (en) 2011-01-28 2012-08-02 Zx Pharma, Llc Controlled-release melatonin composition and related methods
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
WO2013112949A2 (en) * 2012-01-26 2013-08-01 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
CA2872324C (en) 2012-05-18 2017-06-06 Vanda Pharmaceuticals Inc. Metabolites of (1r-trans)-n-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamide
MX377667B (es) * 2012-12-18 2025-03-11 Vanda Pharmaceuticals Inc Uso de un agonista de malatonina para el tratamiento de ritmos circadianos de curso libre.
US10376487B2 (en) * 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
WO2015117048A1 (en) * 2014-01-31 2015-08-06 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
FI3188727T3 (fi) 2014-09-02 2023-02-20 Tasimelteoni smith-magenisin oireyhtymän hoitamiseksi
US10076286B1 (en) 2014-10-21 2018-09-18 Verily Life Sciences Llc Methods and devices for circadian rhythm monitoring
WO2016109359A1 (en) * 2014-12-29 2016-07-07 Auspex Pharmaceuticals, Inc. Cyclopropyl dihydrobenzofuran modulators of melatonin receptors
US11013713B2 (en) * 2015-12-15 2021-05-25 Vanda Pharmaceuticals Inc. Method of treatment
US9884819B2 (en) 2016-01-06 2018-02-06 Auspex Pharmaceuticals, Inc. Tetrahydrocarbazole inhibitors of SIRT1 receptors
US10342873B2 (en) 2016-05-06 2019-07-09 Physician's Seal, LLC Valerian composition and related methods
WO2018033546A1 (en) * 2016-08-18 2018-02-22 Koninklijke Philips N.V. Blood-pressure management
US20210059973A1 (en) 2017-08-02 2021-03-04 Vanda Pharmaceuticals Inc. Treatment of Affective Disorders
KR20240007693A (ko) * 2018-03-04 2024-01-16 반다 파마슈티칼즈, 인코퍼레이티드. 타시멜테온을 이용한 질환의 치료
US11346169B2 (en) 2018-07-23 2022-05-31 Kobold Corporation Sleeve valves, shifting tools and methods for wellbore completion operations therewith
CN108828098B (zh) * 2018-07-24 2020-04-21 山东农业大学 一种高效液相色谱-质谱法测定棉花中褪黑素的方法
EP3849531A1 (en) * 2018-09-12 2021-07-21 Vanda Pharmaceuticals Inc. Improving sleep or post-sleep performance
KR102260252B1 (ko) * 2018-10-24 2021-06-03 주식회사 인코스팜 피부 세포를 통한 일주기 리듬 분석 방법, 일주기 리듬 장애를 정상화하는 방법 및 일주기 리듬 정보를 이용한 정보제공 시스템
CN109522688B (zh) * 2018-10-27 2023-10-13 平安医疗健康管理股份有限公司 基于数据处理的肾功能衰竭资质认证方法、设备及服务器
EP3671757A1 (en) * 2018-12-18 2020-06-24 Koninklijke Philips N.V. System and method for determining a level of alertness
PH12021553135A1 (en) * 2019-06-29 2023-07-03 Vanda Pharmaceuticals Inc Tasimelteon use in treating sleep aberrations
CA3161975A1 (en) * 2019-12-13 2021-06-17 Vanda Pharmaceuticals Inc. Liquid tasimelteon formulations and methods of use thereof

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL50699A0 (en) 1975-10-28 1976-12-31 Ici America Inc Triazole derivatives
EP0126630B1 (en) 1983-05-18 1987-09-16 Monash University The use of melatonin for the manufacture of a medicament
IL79264A0 (en) 1986-06-27 1986-09-30 Univ Ramot Tryptamine derivatives,pharmaceutical compositions containing them and their use in an assay for melatonin receptors
US4997845A (en) 1987-02-02 1991-03-05 Eli Lilly And Company β-alkylmelatonins as ovulation inhibitors
US5093352A (en) 1988-11-14 1992-03-03 Whitby Research, Inc. Antidepressant agents
US5151446A (en) 1989-09-25 1992-09-29 Northwestern University Substituted 2-amidotetralins as melatonin agonists and antagonists
FR2658818B1 (fr) 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US6638963B1 (en) * 1990-12-04 2003-10-28 Oregon Health And Science University Methods for treating circadian rhythm disorders
US5242941A (en) 1990-12-04 1993-09-07 State Of Oregon Methods of treating circadian rhythm disorders
IT1251544B (it) 1991-05-13 1995-05-17 Gabriele Biella Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico
US6180657B1 (en) 1993-11-18 2001-01-30 Eli Lilly And Company Melatonin derivatives for use in treating desynchronization disorders
US5403851A (en) 1994-04-05 1995-04-04 Interneuron Pharmaceuticals, Inc. Substituted tryptamines, phenalkylamines and related compounds
GB9416884D0 (en) 1994-08-20 1994-10-12 Danbiosyst Uk Drug delivery compositions
AT408188B (de) 1995-02-01 2001-09-25 Neurim Pharma 1991 Verwendung von melatonin zur behandlung von an medikamentensucht leidenden patienten
JPH11515014A (ja) 1995-10-24 1999-12-21 グルーエネンタール ゲゼルシャフト ミット ベシュレンクテル ハフツング 哺乳類の概日リズムの調整方法
AU719994B2 (en) 1996-12-10 2000-05-18 Bristol-Myers Squibb Company Benzodioxole, benzofuran, dihydrobenzofuran, and benzodioxane melatonergic agents
US5776969A (en) 1997-02-27 1998-07-07 Eli Lilly And Company Treatment of sleep disorders
AUPO588297A0 (en) * 1997-03-26 1997-04-24 Luminis Pty Limited Mediation in melatonin production
JP3055884B2 (ja) 1997-08-07 2000-06-26 花野商事株式会社 引きクランプ装置
EP1100508B8 (en) 1998-06-09 2004-01-07 Takeda Chemical Industries, Ltd. Pharmaceutical combination comprising a tricyclic compound and at least one of zolpidem, zopiclone and brotizolam for treating or preventing sleep disorders
US6562858B2 (en) 1999-05-17 2003-05-13 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating depression
WO2001002392A1 (en) 1999-06-30 2001-01-11 Bristol-Myers Squibb Company Heterocyclic aminopyrrolidine derivatives as melatonergic agents
EP2295058B1 (en) 2001-10-30 2013-09-04 Novartis AG Depot formulations of iloperidone with a polymer
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds
IL155666A (en) 2003-04-29 2013-12-31 Neurim Pharma 1991 Insomnia treatment
JP2005080603A (ja) * 2003-09-10 2005-03-31 Kumamoto Technology & Industry Foundation 生体リズム障害の度合の判断方法
WO2005063240A1 (en) 2003-12-22 2005-07-14 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of hypertension
CA2551637A1 (en) 2003-12-24 2005-07-14 Sepracor Inc. Melatonin combination therapy for improving sleep quality
GB0400031D0 (en) * 2004-01-03 2004-02-04 Univ Sheffield Depression treatment
EP1919477B1 (en) 2005-07-29 2012-07-11 Vanda Pharmaceuticals Inc. Use of [2-(2-methylimidazol-1-yl)methyl]pyridine for treating sleep disorders
US7754902B2 (en) 2006-05-18 2010-07-13 Vanda Pharmaceuticals, Inc. Ruthenium(II) catalysts for use in stereoselective cyclopropanations
AU2007253701A1 (en) * 2006-05-22 2007-11-29 Vanda Pharmaceuticals, Inc. Melatonin agonist treatment
MX2008014840A (es) 2006-05-22 2008-12-05 Vanda Pharmaceuticals Inc Tratamiento de trastornos depresivos.
WO2008011150A1 (en) 2006-07-20 2008-01-24 Somaxon Pharmaceuticals, Inc. Methods of improving the pharmacokinetics of doxepin
MX2009000659A (es) 2006-07-21 2009-06-08 Univ California Composiciones de polipeptidos de retrovirus endogeno humano y metodo para su uso.
US20110077200A1 (en) 2006-12-06 2011-03-31 Somaxon Pharmaceuticals, Inc. Combination therapy using low-dose doxepin for the improvement of sleep
CN101678025A (zh) 2007-04-11 2010-03-24 生物马林药物股份有限公司 四氢生物蝶呤组合物及其测量方法
CA3159584A1 (en) 2007-09-13 2009-03-19 Vanda Pharmaceuticals Inc. Prediction of sleep parameter and response to sleep-inducing compound based on per3 vntr genotype
WO2009084023A2 (en) 2007-10-19 2009-07-09 Glenmark Generics Limited Amorphous ramelteon and process for the preparation thereof
US20100249164A1 (en) 2007-10-31 2010-09-30 Renger John J Modulation of sleep with nr2b receptor antagonists
JP5558016B2 (ja) 2009-03-17 2014-07-23 株式会社 資生堂 概日リズム調整剤
CA2757858C (en) * 2009-04-07 2017-03-28 Duocort Pharma Ab Improved glucocorticoid therapy
US20120136050A1 (en) 2009-07-16 2012-05-31 Vanda Pharmaceuticals Inc. Use of a melatonin agonist for the treatment of sleep disorders including primary insomnia
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
WO2013112949A2 (en) 2012-01-26 2013-08-01 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
CA2872324C (en) 2012-05-18 2017-06-06 Vanda Pharmaceuticals Inc. Metabolites of (1r-trans)-n-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamide
MX377667B (es) 2012-12-18 2025-03-11 Vanda Pharmaceuticals Inc Uso de un agonista de malatonina para el tratamiento de ritmos circadianos de curso libre.
US10376487B2 (en) * 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
EP3470405A1 (en) 2014-02-12 2019-04-17 Vanda Pharmaceuticals Inc. Highly purified pharmaceutical grade tasimelteon

Also Published As

Publication number Publication date
US20140296332A1 (en) 2014-10-02
US20200009106A1 (en) 2020-01-09
MX374068B (es) 2025-03-05
ES2897671T3 (es) 2022-03-02
KR20190069617A (ko) 2019-06-19
CO7131366A2 (es) 2014-12-01
WO2013112951A2 (en) 2013-08-01
JP2022095662A (ja) 2022-06-28
US20240156775A1 (en) 2024-05-16
CA3085116A1 (en) 2013-08-01
IL233715A0 (en) 2014-09-30
US20180071245A1 (en) 2018-03-15
US20210205261A1 (en) 2021-07-08
CA2861111C (en) 2021-11-23
KR101895653B1 (ko) 2018-09-05
CN104379135B (zh) 2020-07-14
CL2014001993A1 (es) 2015-03-13
RU2014134552A (ru) 2016-03-20
US9060995B2 (en) 2015-06-23
US10945988B2 (en) 2021-03-16
EP3300728A2 (en) 2018-04-04
EP3620794A1 (en) 2020-03-11
BR112014018433A8 (pt) 2017-07-11
WO2013112951A3 (en) 2014-12-31
US10610510B2 (en) 2020-04-07
KR20200123873A (ko) 2020-10-30
CA2861108A1 (en) 2013-08-01
KR102411809B1 (ko) 2022-06-22
JP2021073222A (ja) 2021-05-13
US11918556B2 (en) 2024-03-05
BR112014018433A2 (es) 2017-06-20
CA2861111A1 (en) 2013-08-01
PT2806863T (pt) 2017-11-09
MX2019012197A (es) 2020-08-31
RU2650647C2 (ru) 2018-04-16
JP6267260B2 (ja) 2018-01-24
KR20170058463A (ko) 2017-05-26
USRE46604E1 (en) 2017-11-14
KR102307012B1 (ko) 2021-09-30
RU2631602C2 (ru) 2017-09-25
CA2861108C (en) 2020-09-08
EP2806863A2 (en) 2014-12-03
US11826339B2 (en) 2023-11-28
US20220175716A1 (en) 2022-06-09
WO2013112949A3 (en) 2013-09-19
JP2015508157A (ja) 2015-03-16
US10449176B2 (en) 2019-10-22
JP2015509106A (ja) 2015-03-26
AU2021204784B2 (en) 2024-11-14
MX2014009078A (es) 2016-01-25
AU2016204217A1 (en) 2016-07-14
BR112014018429A8 (pt) 2017-07-11
US11285129B2 (en) 2022-03-29
KR20140116927A (ko) 2014-10-06
SI2806863T1 (sl) 2017-12-29
IL269041A (en) 2019-10-31
KR20190006598A (ko) 2019-01-18
RU2014134555A (ru) 2016-03-20
US20200179326A1 (en) 2020-06-11
JP2016172737A (ja) 2016-09-29
JP2023071727A (ja) 2023-05-23
KR102593047B1 (ko) 2023-10-24
JP2018080181A (ja) 2018-05-24
AU2013211880A1 (en) 2014-08-21
AU2019204306A1 (en) 2019-07-04
US20210161854A1 (en) 2021-06-03
CA3159064A1 (en) 2013-08-01
US11850229B2 (en) 2023-12-26
AU2018201302A1 (en) 2018-03-15
KR20200022543A (ko) 2020-03-03
US20140357710A1 (en) 2014-12-04
CN110215440A (zh) 2019-09-10
US8785492B2 (en) 2014-07-22
HRP20171600T1 (hr) 2017-12-15
US20220168264A1 (en) 2022-06-02
IN2014DN07050A (es) 2015-04-10
US20170100366A1 (en) 2017-04-13
JP2017039731A (ja) 2017-02-23
IL269054A (en) 2019-10-31
US9539234B2 (en) 2017-01-10
MX367184B (es) 2019-08-08
KR20220087582A (ko) 2022-06-24
CA3085116C (en) 2022-07-19
EP2806863B1 (en) 2017-08-09
JP2019038822A (ja) 2019-03-14
ES2646197T3 (es) 2017-12-12
AU2019203910B2 (en) 2021-09-23
EP4502609A2 (en) 2025-02-05
BR112014018429A2 (es) 2017-06-20
US10980770B2 (en) 2021-04-20
AU2016204178A1 (en) 2016-07-14
US20190070144A1 (en) 2019-03-07
AU2021204784A1 (en) 2021-08-05
EP3300728A3 (en) 2018-05-02
US20150216837A1 (en) 2015-08-06
MX2014009079A (es) 2016-01-25
US20240197671A1 (en) 2024-06-20
US20170087123A1 (en) 2017-03-30
KR102317399B1 (ko) 2021-10-26
US20140296330A1 (en) 2014-10-02
HUE034876T2 (hu) 2018-03-28
KR102171965B1 (ko) 2020-10-30
KR20180100450A (ko) 2018-09-10
JP7119261B2 (ja) 2022-08-17
EP2806864A2 (en) 2014-12-03
KR20210118983A (ko) 2021-10-01
CN104379135A (zh) 2015-02-25
IN2014DN07132A (es) 2015-04-24
WO2013112949A2 (en) 2013-08-01
US9855241B2 (en) 2018-01-02
DK2806863T3 (en) 2017-10-30
US20210330634A1 (en) 2021-10-28
EP2806864B1 (en) 2021-08-25
US20140296331A1 (en) 2014-10-02
CL2014001992A1 (es) 2015-03-13
AU2019203910A1 (en) 2019-06-20
US9549913B2 (en) 2017-01-24
US12201604B2 (en) 2025-01-21
JP2020097602A (ja) 2020-06-25
US11833130B2 (en) 2023-12-05
CN111603460A (zh) 2020-09-01
US11633377B2 (en) 2023-04-25
CN104519877A (zh) 2015-04-15
AU2013211878A1 (en) 2014-08-21
IL233714A0 (en) 2014-09-30
MX2020007448A (es) 2020-09-14
AU2018201909A1 (en) 2018-04-12
US10149829B2 (en) 2018-12-11
KR20140117537A (ko) 2014-10-07
US20130197076A1 (en) 2013-08-01
US20220168263A1 (en) 2022-06-02

Similar Documents

Publication Publication Date Title
CO7131366A2 (es) Tratamiento de trastornos del ritmo circadiano
MX2015007909A (es) Tratamiento de trastornos del ritmo circadiano.
CY1124729T1 (el) Φαρμακοτεχνικες μορφες του ενζαλουταμιδιου
CY1124436T1 (el) Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια
CY1119840T1 (el) Δικυκλικως υποκατεστημενες ουρακιλες και η χρηση αυτων
GT201500062S (es) Modelo industrial de instrumento para el cuidado oral
CL2016000354A1 (es) Modulación de la inmunidad tumoral
CL2015002567A1 (es) Compuestos y sus usos para modular la hemoglobina
MX2017014375A (es) Moduladores del ccr2.
CL2015002501A1 (es) Compuestos y usos de estos para la modulación de la hemoglobina
EP2956441A4 (en) MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL
CR20160093A (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub aguda o cronica
MX2018013663A (es) Metodos para tratar trastornos de sueño de ritmo circadiano.
CL2015002835A1 (es) Nuevos derivados de piridina
CL2016001578A1 (es) Piperidiniltetrahidroquinolinas sustituidas y su uso como antagonistas de los adenoreceptores alpha-2c.
CO7461127A2 (es) Código para la configuración de un dispositivo de atención al paciente
UY34082A (es) Derivados de 2-amino-3-(imidazol-2-il)-piridin-4-ona,preparación de los mismos y uso terapéutico de los mismos
ECSP16086232A (es) (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
UY34667A (es) ?método y dispositivo para el tratamiento de trastornos del colesterol en la sangre?.
CR20140526A (es) Dronedarona para uso en la leishmaniosis, formulaciones y asociaciones para uso en la leishmaniosis
AR108472A1 (es) Métodos de tratamiento de los trastornos del ritmo circadiano del sueño
AR099638A1 (es) El uso de 3-carboxi-n-etil-n,n-dimetilpropan-1-aminio o una sal farmacéuticamente aceptable del mismo en la prevención y el tratamiento de la diabetes
CY1118778T1 (el) Ανταγωνιστες υποδοχεα βραδυκινινης και φαρμακευτικες συνθεσεις οι οποιες περιεχουν αυτους
UY35443A (es) Derivados oxindol con un sustituyente oxetano y uso de los mismos para tratar enfermedades relacionadas con la vasopresina
UY34479A (es) Composición farmacéutica que comprende cloruro de isometamidium en solución para el tratamiento de la tripanosomiasis en animales